Targeted imaging - Advantages in the drug discovery pipeline

MALDI imaging offers many advantages for targeted imaging in the drug discovery pipeline. It offers a unique combination of molecular specificity and distribution mapping that neither Quantitative Whole-Body Autoradiography (QWBA) nor LC-MS/MS can deliver.

Compound distribution cannot be measured with LC-MS/MS

When Drug-Related Materials (DRM) are extracted from tissue homogenates for LC-MS/MS analysis, any information about compartmental distribution is lost. Moreover, quantified DRM is presumed to be an average value, equally distributed throughout the tissue, missing potentially toxic amounts of compound that may be localized to very small compartments.

MALDI targeted imaging reveals not only compartmentalized distributions of DRM, but also can provide quantitative measures of compounds within each compartment that is not possible with LC-MS/MS.

MALDI targeted imaging reveals compund localization not detectable with LC-MS/MS

Unsurpassed molecular specificity for label-free distribution monitoring

QWBA is the regulatory standard for distribution monitoring but it carries very high cost per study and cannot distinguish intact molecules from radio-labeled-metabolites. Targeted imaging using a MALDI-MRMS system provides a level of molecular specificity that QWBA cannot deliver and at a much lower operational cost, meaning it can be deployed much earlier in the discovery pipeline.

eXtreme Resolution of solariX XR can spatially differentiate ions that differ by only a few mDa and image multiple compounds per dataset.

MALDI imaging is revolutionizing drug discovery

A recent cover article in Chemical & Engineering News highlighted the adoption of MALDI imaging into the pharmaceutical industry.

Read more

Learn how Imabiotech, the leading global CRO for MALDI imaging services, relies on Bruker’s targeted imaging technology to provide their clients with quantitative DMPK studies for drug discovery.

Label-free targeted imaging and distribution mapping

Compound distribution cannot be measured with LC-MS/MS

Unsurpassed molecular specificity for label-free distribution monitoring

MALDI imaging is revolutionizing drug discovery

Newsletter

LinkedIn

Webinars